Luca Issi
Stock Analyst at RBC Capital
(0.84)
# 3,593
Out of 4,818 analysts
199
Total ratings
20.33%
Success rate
-22.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Luca Issi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Sector Perform | $24 → $21 | $17.55 | +19.69% | 6 | Apr 21, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Sector Perform | $10 → $5 | $2.96 | +68.92% | 7 | Apr 16, 2025 | |
| ASND Ascendis Pharma | Initiates: Outperform | $205 | $159.50 | +28.53% | 1 | Apr 16, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $24 → $20 | $3.70 | +440.54% | 5 | Mar 25, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $310 → $330 | $242.61 | +36.02% | 27 | Mar 21, 2025 | |
| KRRO Korro Bio | Maintains: Outperform | $105 → $95 | $17.42 | +445.35% | 7 | Mar 19, 2025 | |
| SGMO Sangamo Therapeutics | Reiterates: Sector Perform | $2 | $0.81 | +145.46% | 6 | Mar 18, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | $17 | $7.92 | +114.78% | 1 | Mar 18, 2025 | |
| MGTX MeiraGTx Holdings | Maintains: Outperform | $11 → $13 | $6.55 | +98.47% | 6 | Mar 17, 2025 | |
| ALLO Allogene Therapeutics | Reiterates: Outperform | $10 | $1.57 | +536.94% | 8 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $15 | $5.78 | +159.52% | 7 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $39 → $35 | $3.26 | +975.27% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $24 → $26 | $20.17 | +28.94% | 7 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $29.57 | +136.73% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $62.71 | +11.62% | 12 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $40 | $27.39 | +46.04% | 13 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $53 → $48 | $39.08 | +22.82% | 13 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $13.38 | +213.90% | 8 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $14.28 | +68.07% | 6 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $34.93 | +63.18% | 1 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $9.21 | +225.73% | 9 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $67 | $30.92 | +116.69% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $11.13 | +304.49% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.61 | +148.45% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $80 | $4.14 | +1,832.37% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $77 | $37.59 | +104.84% | 3 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $7 → $15 | $6.79 | +120.91% | 5 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $54 | $8.18 | +560.15% | 4 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $0.85 | +1,543.58% | 5 | Aug 7, 2024 |
Apellis Pharmaceuticals
Apr 21, 2025
Maintains: Sector Perform
Price Target: $24 → $21
Current: $17.55
Upside: +19.69%
Adverum Biotechnologies
Apr 16, 2025
Maintains: Sector Perform
Price Target: $10 → $5
Current: $2.96
Upside: +68.92%
Ascendis Pharma
Apr 16, 2025
Initiates: Outperform
Price Target: $205
Current: $159.50
Upside: +28.53%
Lexeo Therapeutics
Mar 25, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $3.70
Upside: +440.54%
Alnylam Pharmaceuticals
Mar 21, 2025
Maintains: Outperform
Price Target: $310 → $330
Current: $242.61
Upside: +36.02%
Korro Bio
Mar 19, 2025
Maintains: Outperform
Price Target: $105 → $95
Current: $17.42
Upside: +445.35%
Sangamo Therapeutics
Mar 18, 2025
Reiterates: Sector Perform
Price Target: $2
Current: $0.81
Upside: +145.46%
Ocular Therapeutix
Mar 18, 2025
Initiates: Outperform
Price Target: $17
Current: $7.92
Upside: +114.78%
MeiraGTx Holdings
Mar 17, 2025
Maintains: Outperform
Price Target: $11 → $13
Current: $6.55
Upside: +98.47%
Allogene Therapeutics
Mar 14, 2025
Reiterates: Outperform
Price Target: $10
Current: $1.57
Upside: +536.94%
Mar 4, 2025
Maintains: Outperform
Price Target: $17 → $15
Current: $5.78
Upside: +159.52%
Mar 3, 2025
Maintains: Outperform
Price Target: $39 → $35
Current: $3.26
Upside: +975.27%
Feb 26, 2025
Maintains: Sector Perform
Price Target: $24 → $26
Current: $20.17
Upside: +28.94%
Feb 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $29.57
Upside: +136.73%
Feb 20, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $62.71
Upside: +11.62%
Feb 18, 2025
Reiterates: Sector Perform
Price Target: $40
Current: $27.39
Upside: +46.04%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $53 → $48
Current: $39.08
Upside: +22.82%
Feb 11, 2025
Reiterates: Outperform
Price Target: $42
Current: $13.38
Upside: +213.90%
Jan 21, 2025
Reiterates: Outperform
Price Target: $24
Current: $14.28
Upside: +68.07%
Jan 21, 2025
Reiterates: Outperform
Price Target: $57
Current: $34.93
Upside: +63.18%
Jan 21, 2025
Reiterates: Outperform
Price Target: $30
Current: $9.21
Upside: +225.73%
Jan 21, 2025
Reiterates: Outperform
Price Target: $67
Current: $30.92
Upside: +116.69%
Jan 14, 2025
Reiterates: Outperform
Price Target: $45
Current: $11.13
Upside: +304.49%
Dec 13, 2024
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.61
Upside: +148.45%
Nov 15, 2024
Reiterates: Sector Perform
Price Target: $80
Current: $4.14
Upside: +1,832.37%
Nov 6, 2024
Reiterates: Outperform
Price Target: $77
Current: $37.59
Upside: +104.84%
Oct 21, 2024
Maintains: Sector Perform
Price Target: $7 → $15
Current: $6.79
Upside: +120.91%
Sep 19, 2024
Reiterates: Outperform
Price Target: $54
Current: $8.18
Upside: +560.15%
Aug 7, 2024
Reiterates: Outperform
Price Target: $14
Current: $0.85
Upside: +1,543.58%